4.8 Article

Precision-Guided Nanospears for Targeted and High-Throughput Intracellular Gene Delivery

期刊

ACS NANO
卷 12, 期 5, 页码 4503-4511

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acsnano.8b00763

关键词

intracellular delivery; nanosphere lithography; nanoneedle; gene delivery; drug delivery; nanorobotics; nanomotor

资金

  1. National Science Foundation [CMMI-1636136]
  2. National Institutes of Health [R21EB016270]
  3. Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA Training Program through its Clinical Fellowship Training Award Program
  4. Hyundai Hope on Wheels Foundation
  5. Alex's Lemonade Stand Foundation for Pediatric Cancer Research
  6. UCLA David Geffen School of Medicine Regenerative Medicine Theme Award
  7. Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA
  8. National Science Foundation of China [51603042]
  9. China Scholarship Council
  10. Royal Thai Government

向作者/读者索取更多资源

An efficient nonviral platform for high-throughput and subcellular precision targeted intracellular delivery of nucleic acids in cell culture based on magnetic nanospears is reported. These magnetic nanospears are made of Au/Ni/Si (similar to 5 mu m in length with tip diameters <50 nm) and fabricated by nanosphere lithography and metal deposition. A magnet is used to direct the mechanical motion of a single nanospear, enabling precise control of position and three-dimensional rotation. These nanospears were further functionalized with enhanced green fluorescent protein (eGFP)-expression plasmids via a layer-by-layer approach before release from the underlying silicon substrate. Plasmid functionalized nanospears are guided magnetically to approach target adherent U87 glioblastoma cells, penetrating the delivery of the plasmid cargo. After 24 h, the target cell expresses green fluorescence indicating successful transfection. This nanospear-mediated transfection is readily scalable for the simultaneous manipulation of multiple cells using a rotating magnet. Cell viability >90% and transfection rates >80% were achieved, which exceed conventional nonviral intracellular methods. This approach is compatible with good manufacturing practices, circumventing barriers to the translation and clinical deployment of emerging cellular therapies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据